Navigation Links
Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
Date:11/1/2007

HAYWARD, Calif., Nov. 1 /PRNewswire/ -- Arete Therapeutics Inc. today announced the initiation of a phase 1 clinical trial for its lead compound, AR9281, for the treatment of hypertension. AR9281 is a "first-in-class," orally-active inhibitor of soluble epoxide hydrolase (s-EH), a novel target for the treatment of hypertension. The trial will enroll up to 32 healthy adult volunteers and will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics for single ascending doses of AR9281.

"AR9281 inhibits s-EH, an enzyme that plays a key role in the cytochrome P450 pathway of arachidonic acid metabolism, and offers a unique mechanism of action as an antihypertensive agent," said Dinesh V. Patel, Ph.D., president and chief executive officer of Arete Therapeutics Inc. "We believe this first-in-class compound has great potential to be a unique 'antihypertensive-plus' drug that not only lowers blood pressure but also offers end organ protection of the heart and kidney, and protection against vascular inflammation."

"The preclinical safety and efficacy profile of AR9281 is very encouraging and provided a solid basis for the initiation of the clinical development phase of this new compound class," commented Randall Whitcomb, M.D., chief medical officer of Arete Therapeutics Inc. "We look forward to reporting results from the initial phase 1 clinical trial in 2008."

Arete Therapeutics' phase 1 single ascending dose, placebo-controlled clinical trial in healthy volunteers will obtain initial safety and tolerance information as well as detailed blood pressure measurements. Levels of s-EH specific biomarkers will be analyzed together with typical inflammatory markers as part of the pharmacodynamic assessment. Following successful completion of the single dose study, Arete plans to initiate a multiple dose phase 1 study, a food effect study, and studies in special populations.

About AR9281

AR9281 is a novel small molecule inhibi
'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. VBI Provides Potential Targets to Diabetes Therapeutics
2. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
3. Bird Flu: Orissa Initiates Protective Measures
4. Biota Initiates Drug Testing War against Common Cold
5. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
6. Government Initiates A Program To Curb HIV
7. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
8. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
9. Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
10. FDA approves Phase 0 trial which tests experimental drugs on humans
11. SARS-Free Taiwan to Mark End Phase of Global Fight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... 06, 2015 , ... In a split second, breaking a bone can cause ... having a fracture through the bone health screenings conducted by American Bone Health trained ... because our residents need this information to remain independent and strong for many more ...
(Date:7/6/2015)... ... July 06, 2015 , ... The School of ... to support a three-year effort to reduce rates of diabetes and cardiovascular disease ... partnership with the Morehouse School of Medicine’s Prevention Research Center and the Satcher ...
(Date:7/6/2015)... ... , ... Dr. Lawrence Green is now offering the newly FDA-approved Kybella injectable ... non-surgical method to dissolve fat cells and is the first of its kind to ... chin, commonly known as a double chin. Dr. Green participated in clinical trials for ...
(Date:7/6/2015)... News, VA (PRWEB) , ... July 06, 2015 ... ... today that Dr. Jeffrey R. Carlson finished his 100th case using SpineFrontier’s® PedFuse® ... Secours Mary Immaculate Hospital in Newport News, VA. The procedure was an L5-S1 ...
(Date:7/6/2015)... OH (PRWEB) , ... July 06, 2015 , ... Thanks ... Home Health and Hospice received the Music & Memory Certification for hospice patients and ... the power of music not only to patients but also to their families and ...
Breaking Medicine News(10 mins):Health News:National Bone Health Screening and Awareness Day 2Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4
... This Summer , , SAN FRANCISCO, July 2 A nationwide ... ( www.metromint.com ), the all-natural mintwater that combines pure water ... and is the perfect refreshment to beat the summer heat. ... the hot summer months: , , , ...
... 2 Allscripts (Nasdaq: MDRX ) ... Beach, SC-based medical billing and consulting agency, has ... management solution for its physician practice clients across ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) , , ...
... Furniture Online ... led to great success in the e-commerce industry. , ... Orem, Utah (PRWEB) July 2, 2009 -- In June 2008, Furniture ... been re-designed so that customers can easily view the out-of-the-box solutions the company presents. Furniture ...
... , , , MCLEAN, Va., July 1 ... of the Association of Organ Procurement Organizations (AOPO). Currently, ... for Donation and Transplant in Albany. The Center for ... Organ Procurement Organization that serves Northeastern New York and Western ...
... Va., July 1 Each year the Association of ... America, recognizes a media outlet that factually reports on ... Crystal Heart Award. The award is supported by the ... 2008 coverage of "Ray of Hope," and ABC,s "Extreme ...
... N.J., July 1 - Data published in the journal, Nicotine ... unplanned and can be a successful route to cessation. In the ... quit attempt started without any advance planning, suggesting that for some ... as once thought. , , While a period of planning ...
Cached Medicine News:Health News:Nationwide Heat Wave Finally Gives Way To Cooling Trend 2Health News:Nationwide Heat Wave Finally Gives Way To Cooling Trend 3Health News:Omega Medical Solutions Selects Allscripts Practice Management and Allscripts Payerpath Revenue Cycle Management 2Health News:Omega Medical Solutions Selects Allscripts Practice Management and Allscripts Payerpath Revenue Cycle Management 3Health News:Omega Medical Solutions Selects Allscripts Practice Management and Allscripts Payerpath Revenue Cycle Management 4Health News:Omega Medical Solutions Selects Allscripts Practice Management and Allscripts Payerpath Revenue Cycle Management 5Health News:Furniture Online's New Look Unveiled 2Health News:Orlowski of Albany to Become Head of Organ Donation Association 2Health News:Crystal Heart Award Presented to Telemundo for Coverage of Organ Donation 2Health News:New Study Shows Many Unplanned Quit Smoking Attempts are Successful 2
(Date:7/6/2015)... Flower Orthopedics, the creator of the ... today that it has received CE marking approval. ... of the innovative FlowerCube™ concept in the European ... Orthopedics, entire product line, which consists of complete ... Consisting of more than 400 implants, including a ...
(Date:7/6/2015)... Research and Markets( http://www.researchandmarkets.com/research/bkw8kk/pharmaceutical ) has ... in North America 2015-2019" report to their offering. ... North America to grow at a CAGR ... International regulations regarding safe drug delivery are enforced by ... adoption of sustainable packaging. Various raw materials such as ...
(Date:7/6/2015)... 2015 E-QURE Corp (OTCQB: EQUR), today announced that ... VirtualInvestorConferences.com on July 9, 2015. DATE: Thursday, July ... This will be a live, interactive ... company questions in real-time - both in the presentation ... If attendees are not able to join the event ...
Breaking Medicine Technology:Flower Orthopedics cleared to enter the European Union 2North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 2North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 3E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2
... VIEW, Calif. , Jan. 28 ChemoCentryx, ... clinical trial of CCX168, an orally-administered small molecule designed ... and very selective compound that specifically targets the C5a ... and a potent driver of the inflammatory response associated ...
... , WARSAW, Ind. , Jan. 28 , ... 7.5% reported over the prior year period (an increase of 2.5% constant currency) ... reported, a decrease of 1.3% from the prior year period, and $1.12 ... , Net Sales of $4.10 billion for the full ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 2ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 3ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 4Zimmer Reports Fourth Quarter and 2009 Financial Results 2Zimmer Reports Fourth Quarter and 2009 Financial Results 3Zimmer Reports Fourth Quarter and 2009 Financial Results 4Zimmer Reports Fourth Quarter and 2009 Financial Results 5Zimmer Reports Fourth Quarter and 2009 Financial Results 6Zimmer Reports Fourth Quarter and 2009 Financial Results 7Zimmer Reports Fourth Quarter and 2009 Financial Results 8Zimmer Reports Fourth Quarter and 2009 Financial Results 9Zimmer Reports Fourth Quarter and 2009 Financial Results 10Zimmer Reports Fourth Quarter and 2009 Financial Results 11Zimmer Reports Fourth Quarter and 2009 Financial Results 12Zimmer Reports Fourth Quarter and 2009 Financial Results 13Zimmer Reports Fourth Quarter and 2009 Financial Results 14Zimmer Reports Fourth Quarter and 2009 Financial Results 15Zimmer Reports Fourth Quarter and 2009 Financial Results 16Zimmer Reports Fourth Quarter and 2009 Financial Results 17Zimmer Reports Fourth Quarter and 2009 Financial Results 18Zimmer Reports Fourth Quarter and 2009 Financial Results 19Zimmer Reports Fourth Quarter and 2009 Financial Results 20Zimmer Reports Fourth Quarter and 2009 Financial Results 21Zimmer Reports Fourth Quarter and 2009 Financial Results 22Zimmer Reports Fourth Quarter and 2009 Financial Results 23Zimmer Reports Fourth Quarter and 2009 Financial Results 24Zimmer Reports Fourth Quarter and 2009 Financial Results 25Zimmer Reports Fourth Quarter and 2009 Financial Results 26Zimmer Reports Fourth Quarter and 2009 Financial Results 27
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: